Publication:
Multidrug resistance in cancer: Understanding molecular mechanisms, immunoprevention and therapeutic approaches

dc.contributor.authorBin Emran, Talha
dc.contributor.authorShahriar, Asif
dc.contributor.authorMahmud, Aar Rafi
dc.contributor.authorRahman, Tanjilur
dc.contributor.authorAbir, Mehedy Hasan
dc.contributor.authorSiddiquee, Mohd. Faijanur-Rob
dc.contributor.authorAhmed, Hossain
dc.contributor.authorRahman, Nova
dc.contributor.authorNainu, Firzan
dc.contributor.authorWahyudin, Elly
dc.contributor.authorMitra, Saikat
dc.contributor.authorDhama, Kuldeep
dc.contributor.authorHabiballah, Mahmoud M.
dc.contributor.authorIslam, Ariful
dc.contributor.authorHassan, Mohammad Mahmudul
dc.contributor.buuauthorHaque, Shafiul
dc.contributor.departmentTıp Fakültesi
dc.contributor.orcid0000-0002-2989-121X
dc.date.accessioned2024-10-08T11:03:07Z
dc.date.available2024-10-08T11:03:07Z
dc.date.issued2022-06-23
dc.description.abstractCancer is one of the leading causes of death worldwide. Several treatments are available for cancer treatment, but many treatment methods are ineffective against multidrug-resistant cancer. Multidrug resistance (MDR) represents a major obstacle to effective therapeutic interventions against cancer. This review describes the known MDR mechanisms in cancer cells and discusses ongoing laboratory approaches and novel therapeutic strategies that aim to inhibit, circumvent, or reverse MDR development in various cancer types. In this review, we discuss both intrinsic and acquired drug resistance, in addition to highlighting hypoxia- and autophagy-mediated drug resistance mechanisms. Several factors, including individual genetic differences, such as mutations, altered epigenetics, enhanced drug efflux, cell death inhibition, and various other molecular and cellular mechanisms, are responsible for the development of resistance against anticancer agents. Drug resistance can also depend on cellular autophagic and hypoxic status. The expression of drug-resistant genes and the regulatory mechanisms that determine drug resistance are also discussed. Methods to circumvent MDR, including immunoprevention, the use of microparticles and nanomedicine might result in better strategies for fighting cancer.
dc.identifier.doi10.3389/fonc.2022.891652
dc.identifier.issn2234-943X
dc.identifier.scopus2-s2.0-85133816283
dc.identifier.urihttps://doi.org/10.3389/fonc.2022.891652
dc.identifier.urihttps://hdl.handle.net/11452/46064
dc.identifier.volume12
dc.identifier.wos000827820300001
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherFrontiers Media Sa
dc.relation.journalFrontiers In Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectEpidermal-growth-factor
dc.subjectCell lung-cancer
dc.subjectTranscriptional down-regulation
dc.subjectHepatocellular-carcinoma cells
dc.subjectTerminal proliferation arrest
dc.subjectPremalignant oral lesions
dc.subjectGlutathione-s-transferase
dc.subjectOvercome drug-resistance
dc.subjectCytotoxic t-lymphocytes
dc.subjectTumor-necrosis-factor
dc.subjectMultidrug resistance
dc.subjectCancer
dc.subjectImmuno-prevention
dc.subjectMicrorna
dc.subjectIntracellular and extracellular atp
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectOncology
dc.titleMultidrug resistance in cancer: Understanding molecular mechanisms, immunoprevention and therapeutic approaches
dc.typeReview
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi
local.indexed.atWOS
local.indexed.atScopus

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Haque_vd_2022.pdf
Size:
2.37 MB
Format:
Adobe Portable Document Format